Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
NCT01540071Phase 2Completed
- Sponsor
- Io Therapeutics, Inc.
- Start
- Aug 2011
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of irx4204 in castration-resistant prostate cancer (CRPC), sponsored by Io Therapeutics, Inc.. Started Aug 2011; status: completed.
02
Drugs
irx4204
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01540071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01540071.